Overview

Diurnal Variation of Exogenous Peptides (Endogenous Insulin Jurgita II)

Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
This is an exploratory trial with two cross-over arms investigating pharmacokinetic profiles of endogenous and exogenous insulin in type 2 diabetes mellitus patients treated with continuous subcutaneous Insulin Aspart infusion and combined with or without intravenous glucose infusion. The order of treatment session will be randomised. Hypotheses: 1. Secretion of endogenous insulin depends on exogenous insulin supply 2. Secretion of endogenous insulin is depends on plasma glucose levels
Phase:
Phase 2
Details
Lead Sponsor:
Aarhus University Hospital
Treatments:
Insulin
Insulin Aspart
Insulin degludec, insulin aspart drug combination
Insulin, Globin Zinc
Insulin, Long-Acting